
Foundations of theranostics
Radioligand therapy (RLT) and radioligand imaging (RLI) offer a novel, theranostic approach to targeting and treating certain types of cancer.1 This section of the Novartis RLT Institute is designed to help health care professionals (HCPs) understand the basic scientific foundations of RLT. By focusing on the science, we aim to demystify radiation and safety concerns and build confidence in offering patients this approach to precision medicine in cancer.
Radiation safety fundamentals
Regulation of RLT safety

In facilities that utilize RLTs, the ownership, use, receipt, and transfer of radioactive materials are governed by national and state laws. These rules and guidelines enable compliance through licensing, overseen by institutional committees and regulatory agencies, to uphold safety standards and proper management of RLTs.2-6
National agencies
US agency | Function related to RLT |
---|---|
US Food and Drug Administration (FDA)2 |
|
Nuclear Regulatory Commission (NRC)2,4-6 |
|
US Department of Transportation (DOT)3 |
|
International Air Transport Association (IATA)3 |
|
State agencies
- State regulation of RLT varies and may fall under a state’s Department of Public Health, Environmental Protection, or Radiation Control2,7
- Over 75% of states, known as Agreement States, have signed agreements with the NRC to assume regulatory authority, while the NRC retains authority in Non-Agreement States7